Pamela Kite Trull
Psychiatric/Mental Health · Birmingham, ALNPI 1891055562
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 498 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,541 and has fallen 72.3% since, to $704 in 2025. Among psychiatric/mental health clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 498 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$963
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$822
- Takeda Pharmaceuticals U.S.A., Inc.$745
- Otsuka America Pharmaceutical, Inc.$729
- Vanda Pharmaceuticals Inc.$716
- Johnson & Johnson$705
- plus $4K from 20 others
What the payments were for
- Food & beverage$8,59899%
- Education$921%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 83 | $963 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $822 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $745 |
| Otsuka America Pharmaceutical, Inc. | 50 | $729 |
| Vanda Pharmaceuticals Inc. | 36 | $716 |
| Johnson & Johnson | 34 | $705 |
| Teva Pharmaceuticals USA, Inc. | 46 | $700 |
| Lundbeck LLC | 36 | $649 |
| Alkermes, Inc. | 36 | $606 |
| Neurocrine Biosciences, Inc. | 24 | $557 |
| Corium, LLC | 14 | $338 |
| Axsome Therapeutics, Inc. | 10 | $226 |
| Bausch Health US, LLC | 7 | $126 |
| Sunovion Pharmaceuticals Inc. | 6 | $111 |
| Supernus Pharmaceuticals, Inc. | 6 | $105 |
| Tris Pharma Inc | 5 | $99 |
| E.r. Squibb & Sons, L.L.C. | 4 | $88 |
| Merck | 5 | $88 |
| Eisai Inc. | 5 | $80 |
| Neos Therapeutics, LP | 4 | $70 |
| Almatica Pharma LLC | 2 | $45 |
| Noven Therapeutics, LLC | 2 | $40 |
| Adlon Therapeutics L.p. | 2 | $32 |
| Alfasigma USA, Inc. | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
How this compares
$8,690 in reported general payments places this provider in the 90th percentile of 378 psychiatric/mental health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 19 | $55,855 |
| RexultiBrexpiprazole | 21 | $36,587 |
| PerserisRisperidone | 13 | $35,429 |
| TrintellixVortioxetine Hydrobromide | 47 | $32,502 |
| Abilify MaintenaAripiprazole | 11 | $28,097 |
| Lurasidone Hcl | 73 | $21,970 |
| Aripiprazole | 63 | $8,274 |
| Ziprasidone Hcl | 42 | $5,556 |
| Trazodone Hcl | 198 | $5,405 |
| Asenapine Maleate | 14 | $4,087 |
| Quetiapine Fumarate | 183 | $3,950 |
| Doxepin Hcl | 108 | $3,770 |
| Paliperidone ErPaliperidone | 23 | $3,741 |
| Vilazodone Hcl | 32 | $3,653 |
| Buspirone Hcl | 174 | $3,057 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $729 | $64,68432 claims |
| Johnson & JohnsonInvega Sustenna | $705 | $55,85519 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $745 | $32,50247 claims |
| Almatica Pharma LLCSertraline Hcl | $45 | $1,08495 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Birmingham
- Yuliya SpencerBirmingham$65K
- David CoffmanBirmingham$13K
- Tiffany WallerBirmingham$12K
- Kellie VaughnBirmingham$12K
- Amanda BoydBirmingham$10K
- Hannah KeslerBirmingham$9K
- Judy ClarkBirmingham$9K
- Jessica AdwellBirmingham$9K
- Lacey PodyBirmingham$7K
- Emily MartinBirmingham$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.